Richard Glassock
Nephrology · Laguna Niguel, CANPI 1649548579
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $120,619 of the $137,957 with a category attached, or 87.4%. It is spread thinly across 26 manufacturers, the largest accounting for just 22.4%. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $802.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocryst Pharmaceuticals, Inc.$31K
- Novartis$29K
- AstraZeneca$16K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$14K
- Otsuka America Pharmaceutical, Inc.$9K
- Travere Therapeutics, Inc.$9K
- plus $30K from 20 others
Across 6 payments — averaging $5691.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$29K
- E.r. Squibb & Sons, L.L.C.$4K
- Omeros Corporation$1K
What the payments were for
- Consulting fees$120,61987%
- Speaking & faculty fees$1,5001%
- Travel & lodging$7,1275%
- Food & beverage$8,6976%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocryst Pharmaceuticals, Inc. | 17 | $30,863 |
| Novartis | 50 | $28,942 |
| AstraZeneca(2 entities) | 19 | $16,337 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $13,993 |
| Otsuka America Pharmaceutical, Inc. | 3 | $9,316 |
| Travere Therapeutics, Inc. | 18 | $8,728 |
| F. Hoffmann-la Roche AG | 4 | $6,588 |
| Omeros Corporation | 6 | $5,901 |
| Mallinckrodt Enterprises LLC | 6 | $4,918 |
| Amgen(2 entities) | 9 | $3,518 |
| Genentech, Inc. | 3 | $2,232 |
| Aurinia Pharma U.S., Inc. | 5 | $1,794 |
| E.r. Squibb & Sons, L.L.C. | 2 | $1,680 |
| Vericel Corporation | 1 | $1,200 |
| Novo Nordisk | 3 | $273 |
| Calliditas Therapeutics US Inc. | 4 | $268 |
| Bayer | 3 | $251 |
| Regeneron Healthcare Solutions, Inc. | 2 | $234 |
| Apellis Pharmaceuticals, Inc. | 4 | $200 |
| Kowa Pharmaceuticals America, Inc. | 1 | $188 |
| Regeneron | 2 | $185 |
| Amarin Pharma, Inc. | 1 | $118 |
| Genentech USA, Inc. | 1 | $91 |
| Esperion Therapeutics, Inc. | 1 | $84 |
| Biogen | 1 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$137,957 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Other nephrology in Laguna Niguel
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.